Isoplexis IPO: Biotech Firm Aims for $125M Market Debut

IsoPlexis Launches IPO to Advance Single-Cell Proteomics

Trading of IsoPlexis shares commenced on Friday, marking a significant step for the company specializing in advanced tools for single-cell analysis. The initial public offering (IPO) is projected to generate approximately $125 million, funds earmarked for bolstering the commercial team and accelerating the development of precision medicine applications.

Company Overview and Core Technology

Established in 2013, IsoPlexis operates within the realm of drug discovery and research laboratories. Its primary focus lies in single-cell proteomics – the detailed study of proteins and their interactions within individual cells. The company has engineered both instruments and software designed to analyze proteins secreted by various cell types, including immune and tumor cells.

A key capability of these instruments is the identification of cells exhibiting high levels of protein secretion. This data is then leveraged to facilitate the creation of novel therapies and to better predict patient responses to existing treatments.

“Superhero Cells” and Market Presence

“The instrument we’ve developed allows us to pinpoint specific cell subsets, which we refer to as ‘superhero cells’,” explains Sean Mackay, CEO and co-founder. “These cells are characterized by heightened activity, often overlooked by conventional technologies.”

As of the first half of the current year, approximately 150 IsoPlexis units have been deployed. The customer base includes 15 prominent global pharmaceutical companies and, according to SEC filings, nearly half of all comprehensive cancer centers within the United States.

Funding and IPO Details

IsoPlexis has successfully secured substantial funding from a number of well-known investors. Prior to the IPO, the company had amassed approximately $205.5 million in funding, as reported by Crunchbase.

The most recent Series D funding round yielded around $135 million, comprising $85 million in equity securities and $50 million in debt financing. Participants in this round included Perceptive Advisors, Ally Bridge Group, and funds managed by BlackRock.

Initial share pricing was set at approximately $15 per share, but the price has since decreased to around $12 at the time of this report.

Linking Cellular Function to Patient Outcomes

A central tenet of IsoPlexis’ approach is its pioneering use of proteomics and single-cell biology to correlate cellular function with patient outcomes. This essentially means the company aims to predict a patient’s prognosis – for example, in cancer – by examining the interactions between individual cells and their proteins.

Published research supports the efficacy of IsoPlexis’ instruments in this regard, particularly within the context of cancer treatment.

CAR-T Cell Therapy Study

A 2021 study published in Nature Medicine utilized IsoPlexis instruments to analyze immune cell activity in lymphoma patients whose cancers had proven resistant to treatment or had relapsed after initial remission. The patients were undergoing CAR-T cell therapy – a treatment involving the injection of genetically modified immune cells to target cancerous cells.

The study revealed that the production of cytokines (proteins crucial for cell signaling) by the CAR-T cells served as a significant indicator of their effectiveness. In effect, the IsoPlexis device helped to identify signals indicating the success of CAR-T cell therapy.

Identifying Predictive Immune Cells

“Our findings demonstrate that the unique cells we identify are indicative of long-term patient response,” states Mackay. “We have published studies across various cancers showing that patients possessing these distinctive immune cells – our ‘superhero cells’ – are more likely to experience sustained positive outcomes.”

Comparison to Flow Cytometry

For those familiar with cellular analysis techniques, IsoPlexis’ technology may bear resemblance to flow cytometry – a widely used method for counting, identifying, and characterizing cells. Established companies like Thermo Fisher Scientific are major players in the flow cytometry market.

However, IsoPlexis contends that its technology provides a novel dimension of information, specifically protein-based data, that is often missed by flow cytometry. The company has licensed a technology enabling the devices to barcode protein activity within each individual cell, known as IsoCode.

A paper in Nature Reviews Chemistry highlights the benefits of barcoding, including the ability to analyze numerous proteins simultaneously across thousands of cells, with the option to recover cells for further experimentation. However, the paper also acknowledges that this technology currently captures only a portion of the complete proteome.

Financial Performance and Future Growth

“This new layer of data, at the individual cell level, is markedly different from existing technologies,” Mackay emphasizes.

Despite its advancements, IsoPlexis is still working towards profitability. SEC filings indicate that the company has experienced net losses in recent years. While revenue increased from $7.5 million in 2019 to $10.4 million in 2020, losses amounted to approximately $13.6 million and $23.3 million, respectively, during those years.

The primary focus for future growth is expanding the deployment of IsoPlexis instruments within the research community. “Our objective is to continue expanding rapidly, serving our current customer base with greater depth, achieved through continued investment in our commercial team,” Mackay concludes.